Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Hopes Esomeprazole Helps Make Private Label OTCs A Bright Spot

Executive Summary

The firm lowers its 2016 guidance as its European branded OTC drug and nutritional product business and its Rx topicals business appear to be major obstacles to escaping its earnings slump.

You may also be interested in...



Perrigo's Rx Business Looks Ready To Sell, Says Hedge Fund Investor

Starboard Value states says Perrigo "severely mismanaged" its entry into branded consumer health through the acquisition of a German firm and showed "misguided confidence" in encouraging shareholders to reject Mylan's tender.

Perrigo Plays To OTC Strength With GoodSense Firm Acquisition

Geiss, Destin & Dunn's GoodSense brand includes more than 1,500 OTC drugs and nutritional products. The deal could help diminish the impact of earnings headwinds on Perrigo's branded consumer health and Rx generic topicals businesses.

Perrigo Plays To OTC Strength With GoodSense Firm Acquisition

Geiss, Destin & Dunn's GoodSense brand includes more than 1,500 OTC drugs and nutritional products. The deal could help diminish the impact of earnings headwinds on Perrigo's branded consumer health and Rx generic topicals businesses.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS118942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel